<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622243</url>
  </required_header>
  <id_info>
    <org_study_id>Bio REB 15-254</org_study_id>
    <nct_id>NCT02622243</nct_id>
  </id_info>
  <brief_title>Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge</brief_title>
  <official_title>Duration of Bronchoprotection of the Long Acting Muscarinic Antagonists Tiotropium and Glycopyrronium Against Methacholine Induced Bronchoconstriction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the duration of protection of single doses of 2 different long acting
      muscarinic antagonists against methacholine induced bronchoconstriction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline methacholine bronchoprotection at 96 hours</measure>
    <time_frame>pre treatment versus 96 hour post treatment</time_frame>
    <description>assessed by dose shift of geometric mean methacholine PC20 data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline methacholine bronchoprotection at 1 hour</measure>
    <time_frame>pre treatment versus 1 hour post treatment</time_frame>
    <description>assessed by dose shift of geometric mean methacholine PC20 data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline methacholine bronchoprotection at 24 hours</measure>
    <time_frame>pre treatment versus 24 hours post treatment</time_frame>
    <description>assessed by dose shift of geometric mean methacholine PC20 data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline methacholine bronchoprotection at 48 hours</measure>
    <time_frame>pre treatment versus 48 hours post treatment</time_frame>
    <description>assessed by dose shift of geometric mean methacholine PC20 data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline methacholine bronchoprotection at 72 hours</measure>
    <time_frame>pre treatment versus 72 hours post treatment</time_frame>
    <description>assessed by dose shift of geometric mean methacholine PC20 data</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 inhalations of 2.5mcg/inhalation tiotropium from Respimat inhaler and 1 inhalation of placebo from Breezehaler 1 hour prior to methacholine challenge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glycopyrronium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 inhalation of 50mcg glycopyrronium from Breezehaler and 2 inhalations from placebo Respimat inhaler 1 hour prior to methacholine challenge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>long acting muscarinic antagonist</description>
    <arm_group_label>tiotropium</arm_group_label>
    <other_name>Spiriva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glycopyrronium</intervention_name>
    <description>long acting muscarinic antagonist</description>
    <arm_group_label>glycopyrronium</arm_group_label>
    <other_name>Seebri</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat</intervention_name>
    <description>inhaler device used to deliver active tiotropium or placebo</description>
    <arm_group_label>tiotropium</arm_group_label>
    <arm_group_label>glycopyrronium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Breezehaler</intervention_name>
    <description>inhaler device used to deliver active glycopyrronium or placebo</description>
    <arm_group_label>tiotropium</arm_group_label>
    <arm_group_label>glycopyrronium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female asthmatics &gt; 19 years of age

          -  baseline methacholine PC20 less than or equal to 4mg/ml

          -  baseline lung function &gt;65% predicted

          -  non-smoker and less than 10 pack year smoking history

        Exclusion Criteria:

          -  use of anticholinergic within 30 days of Visit 1

          -  poorly controlled asthma

          -  pregnant or nursing

          -  respiratory illness within 4 weeks of Visit 1

          -  exposure to an agent that triggered asthma worsening (e.g. allergen) within 4 weeks of
             Visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Cockcroft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asthma Research Lab</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2015</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Don Cockcroft</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Methacholine Chloride</mesh_term>
    <mesh_term>Muscarinic Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>journal publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

